At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 60 enrolled
Drug / intervention
MSP1 42-C1/Alhydrogel +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted May 3, 2006·Updated Jan 21, 2008
In Brief
A Phase 1 clinical trial evaluating MSP1 42-C1/Alhydrogel and CPG 7909 for Malaria. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety of and immune response to a preventive malaria vaccine, MSP1 42-C1/Alhydrogel, in healthy adults. This study will also compare responses to two different doses of the malaria vaccine given with or without the adjuvant CPG 7909.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesUnited States
CollaboratorsJohns Hopkins Bloomberg School of Public Health
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedMay 2006
Primary CompletionJul 2007
TodayJul 2026
First PostedMay 3, 2006
Enrollment StartMar 1, 2006
Primary CompletionJul 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 20.2 years ago
Interventions
MSP1 42-C1/Alhydrogelbiological
Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
CPG 7909biological
Adjuvant